Hexahydrocannabinol and Hexahydrocannabiphorol Poisonings: Data From the Czech Toxicology Information Centre and Effects of Legislative Changes
Pharmacology Research & Perspectives · 2025-10 · 13 (5)
DOI: 10.1002/prp2.70162 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 25.08.2025. Verfasst von Michal Čečrle und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Occupational Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic. Hauptthemen laut MEDLINE: Cannabinol, Dronabinol. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MH CZ - DRO 0064165, COOPERATIO Pharmacology, number.
Abstract (Originalsprache)
Hexahydrocannabinol, a hydrogenated derivative of cannabinol, first came to the Czech Toxicological Information Centre (TIC) following reports of poisonings in May 2022. We conducted a retrospective observational study examining self‐reported cases of hexahydrocannabinol and hexahydrocannabiphorol exposure reported to the TIC from May 17, 2022, to April 30, 2024. Of 236 cases reported, 40 (17%) were excluded. The median age of patients was 18 years (range 1.5–73), with a male predominance of 55.8%. Notably, 39 children under 15 years constituted 19% of the cases. The primary exposure routes were ingestion (196 cases; 67.5%) and inhalation via smoking or vaping (62 cases; 31.5%). The clinical manifestations included neurological (74%), cardiovascular (43.1%), gastrointestinal (42.6%), psychiatric (21%), ocular (24.9%), and metabolic symptoms (14.7%). Physician intervention was required in 172 cases (87.8%). Severity assessment revealed mild symptoms in 119 patients (60.4%), moderate in 66 (33.5%), and severe in 12 (6.1%). Outcomes were favorable with recovery in 98% of cases; no fatalities were reported. Hexahydrocannabinol and hexahydrocannabiphorol exposures primarily resulted in neurological, cardiovascular, gastrointestinal effects, and other symptoms, with several cases being serious. Legislative changes impacting these poisonings require further evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Occupational Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- Toxicological Information Centre, General University Hospital, Prague, Czech Republic.
- Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
ORCID-Profile: Michal Čečrle
Förderung
- MH CZ - DRO 0064165
- COOPERATIO Pharmacology, number
Zitieren
APA
Čečrle, M., Běhounková, M., Kotíková, K., & Zacharov, S. (2025). Hexahydrocannabinol and Hexahydrocannabiphorol Poisonings: Data From the Czech Toxicology Information Centre and Effects of Legislative Changes. Pharmacology Research & Perspectives, 13(5). https://doi.org/10.1002/prp2.70162
Vancouver
Čečrle M, Běhounková M, Kotíková K, Zacharov S. Hexahydrocannabinol and Hexahydrocannabiphorol Poisonings: Data From the Czech Toxicology Information Centre and Effects of Legislative Changes. Pharmacology Research & Perspectives. 2025;13(5). doi:10.1002/prp2.70162
BibTeX
@article{erle2025,
author = {Čečrle, Michal and Běhounková, Milada and Kotíková, Kateřina and Zacharov, Sergej},
title = {Hexahydrocannabinol and Hexahydrocannabiphorol Poisonings: Data From the Czech Toxicology Information Centre and Effects of Legislative Changes},
journal = {Pharmacology Research & Perspectives},
year = {2025},
volume = {13},
number = {5},
doi = {10.1002/prp2.70162}
}
EUVIMED